PT - JOURNAL ARTICLE AU - Poklepovic, Andrew S. AU - Shah, Palak AU - Tombes, Mary Beth AU - Shrader, Ellen AU - Bandyopadhyay, Dipankar AU - Deng, Xiaoyan AU - Roberts, Catherine H. AU - Ryan, Alison A. AU - Hudson, Daniel AU - Sankala, Heidi AU - Kmieciak, Maciej AU - Dent, Paul AU - Malkin, Mark G. TI - Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma AID - 10.1101/2024.04.23.24304634 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.23.24304634 4099 - http://medrxiv.org/content/early/2024/04/24/2024.04.23.24304634.short 4100 - http://medrxiv.org/content/early/2024/04/24/2024.04.23.24304634.full AB - Here we report the results of a single-center phase 2 clinical trial combining sorafenib tosylate, valproic acid, and sildenafil for the treatment of patients with recurrent high-grade glioma (NCT01817751). Clinical toxicities were grade 1 and grade 2, with one grade 3 toxicity for maculopapular rash (6.4%). For all evaluable patients, the median progression-free survival was 3.65 months and overall survival (OS) 10.0 months. There was promising evidence showing clinical activity and benefit. In the 33 evaluable patients, low protein levels of the chaperone GRP78 (HSPA5) was significantly associated with a better OS (p < 0.0026). A correlation between the expression of PDGFRα and OS approached significance (p < 0.0728). Five patients presently have a mean OS of 73.6 months and remain alive. This is the first therapeutic intervention glioblastoma trial to significantly associate GRP78 expression to OS. Our data suggest that the combination of sorafenib tosylate, valproic acid, and sildenafil requires additional clinical development in the recurrent glioma population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01817751Funding StatementThis trial was supported by research funding from the NIH-NCI Cancer Center Support Grant (P30-CA016059; PI: Robert Winn, MD)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Virginia Commonwealth University institutional review board approved the study protocol. All procedures were performed in accordance with the ethical standards of the Helsinki Declaration.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors